BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,312,940 | -18.6% | 1,429,601 | -2.4% | 0.08% | -16.7% |
| Q2 2023 | $119,618,725 | +21.1% | 1,465,377 | +10.1% | 0.09% | +15.4% |
| Q1 2023 | $98,765,289 | -9.1% | 1,331,250 | +1.6% | 0.08% | -12.4% |
| Q4 2022 | $108,596,006 | +19.3% | 1,310,280 | +308.8% | 0.09% | +11.2% |
| Q3 2022 | $91,034,000 | -19.6% | 320,542 | -1.9% | 0.08% | -14.0% |
| Q2 2022 | $113,233,000 | -22.5% | 326,659 | -3.2% | 0.09% | -7.0% |
| Q1 2022 | $146,175,000 | -22.3% | 337,556 | -7.2% | 0.10% | -16.0% |
| Q4 2021 | $188,239,000 | +6.9% | 363,860 | +0.2% | 0.12% | -1.7% |
| Q3 2021 | $176,010,000 | +10.6% | 363,229 | +2.7% | 0.12% | +11.0% |
| Q2 2021 | $159,173,000 | +23.0% | 353,514 | +4.4% | 0.11% | +14.7% |
| Q1 2021 | $129,373,000 | +190.0% | 338,736 | +141.1% | 0.10% | +171.4% |
| Q4 2020 | $44,609,000 | +27.7% | 140,478 | -0.4% | 0.04% | +12.9% |
| Q3 2020 | $34,925,000 | -7.2% | 140,980 | -1.1% | 0.03% | -13.9% |
| Q2 2020 | $37,646,000 | +28.1% | 142,561 | -8.0% | 0.04% | +2.9% |
| Q1 2020 | $29,385,000 | -15.6% | 154,966 | -2.2% | 0.04% | +6.1% |
| Q4 2019 | $34,799,000 | -12.8% | 158,530 | -22.3% | 0.03% | -17.5% |
| Q3 2019 | $39,919,000 | -13.5% | 204,010 | -7.8% | 0.04% | -13.0% |
| Q2 2019 | $46,123,000 | +22.0% | 221,223 | +16.1% | 0.05% | +21.1% |
| Q1 2019 | $37,819,000 | +66.5% | 190,477 | +21.3% | 0.04% | +46.2% |
| Q4 2018 | $22,716,000 | +205.7% | 156,965 | +331.1% | 0.03% | +271.4% |
| Q3 2018 | $7,431,000 | -87.8% | 36,408 | -91.1% | 0.01% | -88.5% |
| Q2 2018 | $60,792,000 | -1.6% | 410,894 | +0.5% | 0.06% | -3.2% |
| Q1 2018 | $61,780,000 | +13.3% | 409,028 | -2.8% | 0.06% | +16.7% |
| Q4 2017 | $54,539,000 | -18.9% | 420,989 | -24.3% | 0.05% | -20.6% |
| Q3 2017 | $67,263,000 | -21.8% | 556,401 | -23.9% | 0.07% | -23.6% |
| Q2 2017 | $85,962,000 | +217.7% | 731,589 | +174.8% | 0.09% | +217.9% |
| Q1 2017 | $27,058,000 | +4024.7% | 266,191 | +4340.2% | 0.03% | +2700.0% |
| Q3 2016 | $656,000 | -3.0% | 5,995 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $676,000 | -5.8% | 5,995 | -21.1% | 0.00% | 0.0% |
| Q1 2016 | $718,000 | +115.6% | 7,596 | +105.2% | 0.00% | – |
| Q4 2015 | $333,000 | -74.9% | 3,702 | -74.2% | 0.00% | -100.0% |
| Q3 2015 | $1,327,000 | -3.2% | 14,350 | +3.1% | 0.00% | 0.0% |
| Q2 2015 | $1,371,000 | +8.9% | 13,922 | +10.9% | 0.00% | +100.0% |
| Q1 2015 | $1,259,000 | +30.7% | 12,554 | +20.5% | 0.00% | 0.0% |
| Q4 2014 | $963,000 | – | 10,418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |